21 Apr 2025
💊FDA Announces Joint Meeting on Opioid Analgesics Regulation
Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice-Extended-Release/Long-Acting Opioid Analgesic Postmarketing Requirement
Summary
The Food and Drug Administration (FDA) is announcing an amendment to the notice of joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. This meeting was announced in the Federal Register of December 9, 2024. The amendment is being made to reflect changes in the DATES, ADDRESSES, and Procedure portions of the document. There are no other changes.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$ - Med
The notice pertains to a regulatory meeting that directly impacts businesses involved in opioid analgesics by outlining procedures for public comment and compliance concerning postmarketing requirements, thus highlighting regulatory requirements for drug manufacturers.